Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine-intensified salvage program with PBSC mobilization and autologous transplant for relapsed or resistant CD20-positive follicular lymphoma
2010-018866-21Phase 2Active
- Sponsor
- AIL
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine, oxaliplatin and rituximab in follicular lymphoma (FL), sponsored by AIL. Primary endpoint: Safety. Started Jul 2010; status: active.
02
Drugs
bendamustineoxaliplatinrituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2010-018866-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018866-21.